Catching chances

The movement to be on the ground and research ready before an outbreak

David Brett-Major, James V Lawler

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

After more than 28,000 Ebola virus disease cases and at least 11,000 deaths in West Africa during the 2014–2016 epidemic, the world remains without a licensed vaccine or therapeutic broadly available and demonstrated to alleviate suffering. This deficiency has been felt acutely in the two, short, following years with two Ebola virus outbreaks in the Democratic Republic of Congo (DRC), and a Marburg virus outbreak in Uganda. Despite billions of U.S. dollars invested in developing medical countermeasures for filoviruses in the antecedent decades, resulting in an array of preventative, diagnostic, and therapeutic products, none are available on commercial shelves. This paper explores why just-in-time research efforts in the field during the West Africa epidemic failed, as well as some recent initiatives to prevent similarly lost opportunities.

Original languageEnglish (US)
Article number439
JournalViruses
Volume10
Issue number8
DOIs
StatePublished - Aug 19 2018

Fingerprint

Western Africa
Disease Outbreaks
Ebola Hemorrhagic Fever
Marburgvirus
Ebolavirus
Democratic Republic of the Congo
Uganda
Psychological Stress
Research
Vaccines
Therapeutics

Keywords

  • Emergency clinical management research
  • Filovirus
  • Global health
  • Medical countermeasures review

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology

Cite this

Catching chances : The movement to be on the ground and research ready before an outbreak. / Brett-Major, David; Lawler, James V.

In: Viruses, Vol. 10, No. 8, 439, 19.08.2018.

Research output: Contribution to journalReview article

@article{35bd284ba173422f918592a933af9ed1,
title = "Catching chances: The movement to be on the ground and research ready before an outbreak",
abstract = "After more than 28,000 Ebola virus disease cases and at least 11,000 deaths in West Africa during the 2014–2016 epidemic, the world remains without a licensed vaccine or therapeutic broadly available and demonstrated to alleviate suffering. This deficiency has been felt acutely in the two, short, following years with two Ebola virus outbreaks in the Democratic Republic of Congo (DRC), and a Marburg virus outbreak in Uganda. Despite billions of U.S. dollars invested in developing medical countermeasures for filoviruses in the antecedent decades, resulting in an array of preventative, diagnostic, and therapeutic products, none are available on commercial shelves. This paper explores why just-in-time research efforts in the field during the West Africa epidemic failed, as well as some recent initiatives to prevent similarly lost opportunities.",
keywords = "Emergency clinical management research, Filovirus, Global health, Medical countermeasures review",
author = "David Brett-Major and Lawler, {James V}",
year = "2018",
month = "8",
day = "19",
doi = "10.3390/v10080439",
language = "English (US)",
volume = "10",
journal = "Viruses",
issn = "1999-4915",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",

}

TY - JOUR

T1 - Catching chances

T2 - The movement to be on the ground and research ready before an outbreak

AU - Brett-Major, David

AU - Lawler, James V

PY - 2018/8/19

Y1 - 2018/8/19

N2 - After more than 28,000 Ebola virus disease cases and at least 11,000 deaths in West Africa during the 2014–2016 epidemic, the world remains without a licensed vaccine or therapeutic broadly available and demonstrated to alleviate suffering. This deficiency has been felt acutely in the two, short, following years with two Ebola virus outbreaks in the Democratic Republic of Congo (DRC), and a Marburg virus outbreak in Uganda. Despite billions of U.S. dollars invested in developing medical countermeasures for filoviruses in the antecedent decades, resulting in an array of preventative, diagnostic, and therapeutic products, none are available on commercial shelves. This paper explores why just-in-time research efforts in the field during the West Africa epidemic failed, as well as some recent initiatives to prevent similarly lost opportunities.

AB - After more than 28,000 Ebola virus disease cases and at least 11,000 deaths in West Africa during the 2014–2016 epidemic, the world remains without a licensed vaccine or therapeutic broadly available and demonstrated to alleviate suffering. This deficiency has been felt acutely in the two, short, following years with two Ebola virus outbreaks in the Democratic Republic of Congo (DRC), and a Marburg virus outbreak in Uganda. Despite billions of U.S. dollars invested in developing medical countermeasures for filoviruses in the antecedent decades, resulting in an array of preventative, diagnostic, and therapeutic products, none are available on commercial shelves. This paper explores why just-in-time research efforts in the field during the West Africa epidemic failed, as well as some recent initiatives to prevent similarly lost opportunities.

KW - Emergency clinical management research

KW - Filovirus

KW - Global health

KW - Medical countermeasures review

UR - http://www.scopus.com/inward/record.url?scp=85052117035&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052117035&partnerID=8YFLogxK

U2 - 10.3390/v10080439

DO - 10.3390/v10080439

M3 - Review article

VL - 10

JO - Viruses

JF - Viruses

SN - 1999-4915

IS - 8

M1 - 439

ER -